Egawa K, Kasai N
Microbiol Immunol. 1979;23(2):87-94. doi: 10.1111/j.1348-0421.1979.tb00444.x.
Inhibitory effects of the endotoxic glycolipid from Salmonella minnesota R595 on hepatic drug-metabolizing enzyme activities in mice were investigated, and the depressor activity of the glycolipid in the enzyme systems was confirmed. Among degradation products of lipopolysaccharides tested, lipid A preparations derived from the mild acetic acid hydrolysates of lipopolysaccharides were the most active, but the lipid A fractions prepared from the hydrolysates with 1 N-HCl were almost inactive. A degraded polysaccharide fraction from E. coli lipopolysaccharide was inactive. The activities of the glycolipid and the lipid A preparation were markedly reduced by treatment with alkaline-hydroxylamine, mild alkali or hydrazine. The data showed that the lipid A moiety of the glycolipid may be responsible for the inhibitory activity on the hepatic drug-metabolizing enzyme systems.
研究了来自明尼苏达沙门氏菌R595的内毒素糖脂对小鼠肝脏药物代谢酶活性的抑制作用,并证实了该糖脂在酶系统中的降压活性。在所测试的脂多糖降解产物中,源自脂多糖温和乙酸水解产物的脂质A制剂活性最高,但用1 N - HCl水解产物制备的脂质A组分几乎无活性。大肠杆菌脂多糖的降解多糖组分无活性。用碱性羟胺、温和碱或肼处理后,糖脂和脂质A制剂的活性显著降低。数据表明,糖脂的脂质A部分可能是对肝脏药物代谢酶系统产生抑制活性的原因。